Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Clin Cancer Res. 2011 Jun 20;17(15):5038–5047. doi: 10.1158/1078-0432.CCR-11-0358

Figure 5. Effects of selumetnib on the expression of survivin, Stat3, and markers of cell death.

Figure 5

A) HCT116 cells were exposed to 15 μM 5-FU, 250 nM selumetinib, or the combination prior to irradiation with 4 Gy. Lysates were collected at 24 hours (survivin and stat3) and 48 hours (PARP and caspase-3) after irradiation. Blots are representative of at least 2 independent experiments. B) HCT116 cells were treated as above with 5-FU, selumetinib, the combination, or vehicle prior to irradiation to 4 Gy and collected at 24 hours after IR for cell cycle analysis. No significant difference was observed between the percentage of cells in G2 and M phases of the cell cycle in any group.